Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.65 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 5/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.43 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | OTC | P00480 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL7543431 | 1.00 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL2143365 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL714211 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL292022 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL11660904 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL301606 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL8957537 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL15022773 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL3516723 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 | |
| Arginine SCHEMBL4954180 | 0.94 | GSR (0.65) | GSRGNAI3GNAO1GNAI1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283176-A1 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS LTD. (FI) | 2012-11-08 | — | — | US | claimed |
| US-20020049301-A1 | Short peptides which selectively modulate the activity of serine/threonine kinases | THE CHILDREN'S MEDICAL CENTER CORP. (US) | 2002-04-25 | — | — | US | claimed |
| US-6174993-B1 | DERIVATIVE OF HJ LOOP WHICH IS 5 TO 20 AMINO ACIDS LONG; ANTICARCINOGENIC AGENTS; ANTIINFLAMMATORY AGENTS; ANTIDIABETIC AGENTS; TREATMENT OF OBESITY, AUTOIMMUNE DISORDERS, AND CARDIOVASCULAR DISORDERS | THE CHILDREN'S MEDICAL CENTER CORP. | 2001-01-16 | — | — | US | claimed |
| EP-0983346-A2 | SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES | The Children's Medical Center Corporation (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998053050-A2 | SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283176-A1 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF | ELOVL5, TLR5, VIP | GSR 3965/4885GNAI3 2188/4885GNAO1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.